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Abstract [Limit 250 words, currently 249] 
Background: One of the therapy goals for Crohn’s disease (CD) is glucocorticoid-free remission. 
Studies have shown care setting-specific variations in inflammatory bowel disease (IBD) 
management.  
Aims: The principal objective of this study was to assess concordance between patient-reported 
and physician-reported outcomes in two different care settings (IBD centers and community 
practices).   
Methods: Overall and long-term (≥3 months) glucocorticoid, immunosuppressant and biologics 
use in participants ≥18 years old with a confirmed diagnosis of CD were collected. HCPs were 
grouped by inflammatory bowel disease (IBD) centers and community practices. Quality of life 
(using EuroQol 5D [EQ-5D]) and work/activity days lost were assessed. Agreement between 
patients’ and HCPs’ responses to survey questions was tested using kappa statistics. 
Results: Data from 812 patients were examined. Significantly more patients vs. HCPs reported 
oral glucocorticoid use (25.9% vs. 20.8%, kappa=0.735, P<0.0001). Long-term use of oral 
glucocorticoids was similar for patients vs. HCPs (67.7% vs. 63.8%, kappa=0.598, p=0.53). 
Immunosuppressant use was 52.4% vs. 51.1% (kappa=0.784) and biologics use was 49.5% vs. 
47.0% (kappa=0.909) for patients vs. HCPs. Patients and HCPs reported greater rates of 
symptom improvement with vs without biologic therapy (patients: 33.3% vs 16.8%; HCPs: 
29.3% vs 13.5%, both P<0.001).  Patients with vs. without routine follow-up were less likely to 
be treated with long-term glucocorticoid monotherapy (10.3% vs. 20.7%, P<0.01) and had 
fewer lost work/activity days (5 vs. 8 days, P<0.05). 
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Conclusions: Routine follow-up and higher rates of biologic use are associated with 
improvement in disease symptoms and general health among patients with Crohn’s disease. 
 
Keywords: Crohn’s disease; glucocorticoids; patient-reported outcomes; physician-reported 
outcomes; quality of life 
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Introduction 
Crohn’s disease (CD) is a chronic gastrointestinal (GI) inflammatory condition with potentially 
debilitating symptoms that can lead to serious complications, disabilities and reduced quality of 
life.[1-5] CD affects substantial numbers of patients worldwide, with prevalence of 322 per 
100,000 persons in Europe and 319 per 100,000 persons in North America.[6] 
 
Therapy for CD depends on the location and severity of the disease, as well as any disease-
associated complications.[7,8] Treatment may include aminosalicylates, glucocorticoids, 
immunomodulators, tumor necrosis factor antagonists, other biologics such as integrin blockers 
and IL-12/23 p40 inhibitors, and/or surgery.[8-10] Glucocorticoid therapy has been shown to 
induce remission in patients with moderate to severe CD.[11-15] However, glucocorticoid 
therapy is associated with a number of serious side effects, including osteoporosis, glaucoma, 
cataracts, hypertension, diabetes and increased risk of infections,[16-23] which makes the long-
term use of glucocorticoids undesirable. Thus, while it may be necessary to use glucocorticoid 
therapy to rapidly induce remission and/or quickly reduce moderately severe or severe CD 
symptoms associated with acute flares, one of the goals of CD therapy is glucocorticoid-free 
remission. 
 
Studies have shown country-specific and care setting-specific variations in inflammatory bowel 
disease (IBD) care.[24-27] This variation can lead to differences in quality of care and clinical 
outcomes. Information on the rates of important outcomes of disease control, such as 
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glucocorticoid-free remission, CD-related surgery and hospitalization, and patients’ quality of 
life in IBD centers or in real-life practice, is limited.  
 
The principal objective of this study was to assess concordance between patient-reported and 
physician-reported data from centers in two different practice settings: community practice 
and IBD center. Patient-reported outcome measures included rates of glucocorticoid-free 
remission (defined as no glucocorticoid use in the 3 months before the survey was conducted), 
CD-related hospitalization and surgery, patients’ general quality of life, and days lost from work 
or inability to perform normal activities because of CD. 
 
Methods 
Study Design 
This was a cross-sectional study using a paper-based questionnaire, POLARIS (Practice Patterns 
with InflammatOry Bowel Disease HeaLth CARe Assessment QuestIonnaireS), administered to 
patients and their HCPs. Patients and their HCPs completed their questionnaires on the same 
day, separately. The questions were designed to obtain information about the course of CD, the 
level of CD-related symptoms, patient characteristics and treatment information. The study was 
conducted from July 11, 2012 to November 28, 2012. 
 
Patients  
Patients ≥18 years old with a confirmed diagnosis of CD, disease duration ≥1 year, and ≥2 visits 
with a participating HCP (consulting gastroenterologist, nurse practitioner, or physician’s nurse) 
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at IBD centers and community practices in Canada and Germany were eligible to participate in 
the study. IBD centers were specialized patient care centers that were part of a network of 
cooperating practices with physicians who focus on diagnostic and treatment services for 
individuals with IBD.[28] A diagnosis of CD was confirmed by endoscopy, radiologic evaluation, 
histology or surgical pathology (or investigator’s discretion if some of these details were not 
available). 
 
Ethical considerations 
The study protocol was approved by independent Medical Research Ethics Committees in 
agreement with local legal requirements in Canada and Germany. All patients provided written 
informed consent before participating in the study. Consenting patients were also asked to sign 
and date a form indicating that they were willing to have their HCP supply additional 
information about their condition and their current and previous CD treatment. To protect 
disclosure of patient identities, a unique identification number was assigned to each patient 
before collection of data; this identification number was used on both the patient and HCP 
questionnaires. No patient identifiable information was included in any of the information 
collected. 
 
Questionnaires 
The HCP and patient questionnaires are included in Appendix 1 and Appendix 2, respectively. 
HCPs were asked when each patient was diagnosed with CD, where the disease was located, 
whether the patient had upper GI disease or perianal disease, and whether the patient received 
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therapy with biologics or immunosuppressants during the year before the survey was 
conducted. HCPs were also asked whether their patients received any oral glucocorticoid 
monotherapy (excluding budesonide) or glucocorticoids in combination with other therapies 
and the length of use during the year before the survey was conducted. HCPs were asked if 
their patients were hospitalized for reasons related to CD and if their patients had undergone 
CD-related surgery (i.e. laparotomy or fistula drainage) in the year before the survey was 
conducted. The HCP questionnaire also contained questions about patient referral source and 
frequency of HCP follow-up. Finally, HCPs were asked to select a statement along with a disease 
symptoms curve that best represented the course of the patient’s disease over the past 12 
months before the questionnaire was completed: improvement (a decrease in the severity of 
bowel symptoms during the previous year), worsening (an increase in the severity of bowel 
symptoms during the previous year), continuous and severe bowel symptoms, periods of 
relapse and periods of severe symptoms, or no symptoms or very mild symptoms throughout 
the past year.  
 
The patient’s questionnaire asked for the patient’s age; sex; smoking history; use of 
medications, including oral glucocorticoid use; length of medication use during the year before 
the questionnaire was completed and how often they had routine follow-up appointments. The 
disease statement and symptom curve given to the HCPs was included. Patients were also 
asked whether they had been in the hospital or had surgery because of their CD in the year 
before completing the survey. To assess general quality of life, patients were asked to complete 
the EQ-5D questionnaire. The minimally important difference for the EQ-5D utility is 
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approximately 0.08 (range: 0 = worst health scenario to 1.0 best health scenario), and higher 
scores represent better quality of life.[29] Patients were asked to rate their health state at the 
time of the survey on a scale of 0 to 10, where 0 represented the worst imaginable health state 
and 10 the best imaginable health state. Patients were also asked how many days they had not 
been able to work or go about their normal activities because of their CD during the month 
before completing the questionnaire. Brand names of biologics and azathioprine, 
mercaptopurine, and methotrexate were provided to patients to facilitate recall and minimize 
bias. Budesonide and its brand name were also provided, although budesonide was not 
counted in glucocorticoid use in this survey. The brand names of other glucocorticoids were not 
provided; however, the research coordinator who handed out the survey was available to 
answer any questions or provide clarification to patients at the time the survey was completed. 
 
Only paired surveys were included in the study. Patients and HCPs were blinded to each other’s 
response. HCPs were aware that patients would be completing a questionnaire but were not 
aware of the exact nature of the questions. 
 
Data analysis 
Demographics and disease characteristics of the surveyed population as well as CD treatment 
patterns, measures of symptoms and disease control were summarized using descriptive 
statistics. Outcomes, including referral source, glucocorticoid sparing medications (i.e. anti-TNF 
biologics, immunosuppressants), glucocorticoid use, disease course and selected patient-
reported outcomes, were evaluated and compared by the type of facility (IBD center or 
13 
 
community practice), whether the patients had routine follow-up, and whether the patients 
received biologic therapy.  
 
Chi-square tests and t-tests were used to determine differences between groups for categorical 
and continuous variables, respectively. For quality of life assessments, differences between 
groups were assessed using analysis of variance. Agreement between patients’ and HCPs’ 
responses to survey questions was tested and inter-rater agreement was evaluated using 
Cohen’s kappa statistics. The literature has proposed the following for strength of agreement 
for the kappa coefficient: 0–0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 
as substantial and 0.81–1 as almost perfect agreement.[30] 
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Results 
Study population 
A total of 809 HCPs (430 in Canada and 379 in Germany) and corresponding 812 CD patients 
were identified. Questionnaires were completed and analyzed by 798 (98.3%) patients and 809 
(100%) HCPs. There were 560 (69.0%) patients seen by HCPs in IBD centers and 252 (31.0%) 
patients in community practices. The average age of the study population was 41 years and 
55.3% were women (Table 1). Patients who responded to the questionnaire reported that they 
had CD for approximately 14 years on average. Most patients had ileocolonic CD without upper 
GI disease or perianal disease.  
 
Different patterns were observed regarding the patient referral source at IBD centers vs. 
community practices. At IBD centers, approximately half of the patients (53.2%) were self-
presenting or referred by a general practitioner and the other half (46.8%) were referred by a 
specialist or surgeon. In contrast, at community practices 92.3% of patients were self-
presenting or referred by a general practitioner and only 7.7% were referred by a specialist or 
surgeon. Although there were differences in the patient referral source, the mean disease 
duration since diagnosis was similar between patients at IBD centers and community practices. 
 
Use of oral glucocorticoids 
Significantly more patients vs. HCPs reported any oral glucocorticoid use (as monotherapy or 
combined with other therapies) (25.9% vs. 20.8%, kappa = 0.735, P<0.0001). Patients vs. HCPs 
reported also on the use of glucocorticoids as follows: oral glucocorticoid monotherapy (4.4% 
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vs. 3.7%, kappa = 0.514, p=0.26); long-term (≥3 months continuous use) use of any oral 
glucocorticoid including monotherapy or therapy combined with other therapies (67.7% vs. 
63.8%, kappa = 0.598, p=0.53); and long-term (≥3 months continuous use) use of oral 
glucocorticoid monotherapy (11.6% vs. 7.2%, kappa = 0.433, p=0.74) (Figure 1). Agreements 
between patients and their HCPs were much lower in community practices than in IBD centers 
in all glucocorticoid use measures: use of any oral glucocorticoid (kappa = 0.609 vs. 0.781), use 
of oral glucocorticoid monotherapy (0.425 vs. 0.575), long-term (≥3 months) use of any oral 
glucocorticoid (0.263 vs. 0.663), and long-term (≥3 months) use of oral glucocorticoid 
monotherapy (0.250 vs. 0.520).  
 
Use of glucocorticoid-sparing medications 
Overall, responses from patients and their HCPs were similar regarding use of 
immunosuppressants (52.4% vs. 51.1%, kappa = 0.784; Figure 2) and biologics (49.5% vs. 47.0%, 
kappa=0.909; Figure 3), with lower agreements observed in community practices than in IBD 
centers (use of immunosuppressants: kappa = 0.715 vs. 0.807; use of biologics: kappa = 0.861 
vs. 0.928). 
 
Improved disease course during the past year 
HCPs at IBD centers reported that a greater percentage of their patients had improvement in 
CD-related symptoms compared with HCPs at community practices (26.1% vs. 9.2%, P<0.001; 
Figure 4). HCPs also reported greater rates of symptom improvement among patients who 
received biologics compared with those who did not receive biologics (29.3% vs. 13.5%, 
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P<0.001). Patients who received biologic therapy were also more likely to report that their 
health had improved during the past year compared with patients not receiving biologics 
(33.3% vs. 16.8%, P<0.001). In addition, moderate to high agreement was observed (63.5% 
[502/790]) between HCPs and patients in reporting the change of the disease course. 
 
Overall, HCPs reported fewer CD-related hospitalizations (13.2% vs. 19.5%, P<0.0001) and 
fewer CD-related surgeries (6.2% vs. 10.6%, P<0.0001) during the past year than their patients. 
HCPs at IBD centers reported more CD-related hospitalizations (15.7% vs. 8.0%; P=0.003) and 
more CD-related surgeries (7.0% vs. 4.4%; P=0.16) compared with HCPs at community practices.  
 
Quality of life and health state in patients with and without routine follow-up 
On the IBD health care assessment questionnaire, patients were asked how often (i.e. every 
3 months, every 6 months, every year, or do not have routine follow-up appointments) they 
attended the IBD clinic for routine follow-up appointments. Patients treated at community 
practices were more likely to report that they did not have routine follow-up appointments 
with their HCPs compared with those treated at IBD centers (30.9% vs. 8.6%; P<0.01). 
Significantly greater quality of life, as assessed by higher mean EQ-5D scores (0.8 vs. 0.7, 
P<0.01) and higher patient mean health state scale scores (7.1 vs. 6.3, P<0.01), were observed 
in patients with routine follow-up vs. those without routine follow-up. In addition, significantly 
fewer work/activity days (median: 5 days vs. 8 days, P<0.05) were lost among patients with 
routine follow-up vs. those without routine follow-up care. Patients who received routine 
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follow-up were also less likely to be treated with long-term glucocorticoid monotherapy than 
those who did not have routine follow-up (10.3% vs. 20.7%, P<0.01).  
 
Discussion 
In this cross-sectional study, we assessed treatment patterns, quality of care and level of 
disease control in IBD centers and community practices from the perspective of patients with 
CD and their HCPs. We found that use of agents that provide alternatives to long term use of 
glucocorticoids (oral immune suppressants and anti-TNF therapy) was relatively high, 
particularly at IBD centers in which more than half of the patients were receiving these agents. 
The frequency of patients receiving long-term glucocorticoid monotherapy was lower in IBD 
centers compared with community practices. The higher use of glucocorticoid-sparing 
treatments to reduce adverse effects associated with long-term glucocorticoid use in IBD 
centers is consistent with current guidelines on the treatment of CD.[31]  
 
Results of this cross-sectional survey revealed discordance between patients’ self-reports and 
their HCPs’ documentation regarding use of glucocorticoids. This discordance in the reporting 
of oral glucocorticoid use was more marked in community practices than in IBD centers. There 
are at least two possible explanations for the discrepancy. First, HCPs may underestimate the 
extent of long-term glucocorticoid therapy by their patients, and second, patients may self-
medicate with glucocorticoids. Either way, these findings suggest that communications 
between patients and HCPs may be suboptimal in certain instances. Improvements in care, 
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including routine follow-up and enhanced communication during visits, may serve to improve 
discordance. Currently, standards are being set to reduce variation in the quality of care.[32,33]  
 
Patients treated with biologics were in better symptomatic disease control in comparison with 
those not receiving biologics. Regular routine follow-up appointments were more common for 
patients treated in IBD centers and patients receiving routine follow-ups appeared to have a 
lower frequency of long-term glucocorticoid monotherapies, better quality of life, improvement 
in symptoms and fewer work/activity days lost during the month before completing the 
questionnaire. The best care for patients with CD may come from IBD centers where a team of 
individuals specializing in different aspects of treatment is available to meet the needs of 
different patients, or of a single patient, as treatment needs over time change.[34,35] 
 
Results of this survey need to be interpreted while keeping in mind possible sources of bias. 
There is currently no standard definition of what constitutes an IBD center. In our study, the 
centers were identified as an IBD center or a community practice by the principal investigators 
in the countries (Canada and Germany) where the survey was conducted. There might be 
variation in clinical practice and HCP/patient behavior between the two countries. It is possible 
that patients treated at IBD centers have more severe disease and therefore receive more 
aggressive treatment than those at community practices, which may explain why a greater 
percentage of patients had CD-related hospitalizations and CD-related surgeries at IBD centers 
compared with patients being treated at community practices. The survey did not collect 
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information on strictures and non-perianal fistula, so we are not able to comment on these 
complications. 
 
In summary, results of this cross-sectional survey showed that patients who received more 
routine monitoring of their disease progression had greater symptom relief and had fewer lost 
work or activity days. 
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Tables 
Table 1. Baseline demographics and clinical characteristics of patients with Crohn’s disease 
Characteristic IBD Center Community Practice 
 (N = 560) (N = 252) 
Age   
N  560 249 
Mean ± SD, years 39.8 ± 14.3 42.3 ± 13.7 
Sex   
N 560 249 
Women, n (%) 302 (53.9) 145 (58.2) 
Smoking status   
N 559 249 
Current, n (%) 108 (19.3) 72 (28.9) 
Former, n (%) 174 (31.1) 101 (40.6) 
Never, n (%) 277 (49.6) 76 (30.5) 
Years since CD diagnosis (per physician)   
N 558 251 
Mean ± SD 13.2 (10.2) 14.3 (8.7) 
Disease locationa   
N 560 252 
Terminal ileum, n (%) 391 (69.8) 175 (69.4) 
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Colon, n (%) 389 (69.5) 213 (84.5) 
Jejunum/ileum, n (%) 39 (7.0) 23 (9.1) 
No location checked, n (%) 3 (0.5) 3 (1.2) 
Upper GI disease?   
N 552 251 
Yes, n (%) 47 (8.5) 17 (6.8) 
No, n (%) 490 (88.8) 231 (92.0) 
Not sure, n (%) 15 (2.7) 3 (1.2) 
Perianal disease?   
N 552 250 
Yes, n (%) 135 (24.5) 40 (16.0) 
No, n (%) 409 (74.1) 209 (83.6) 
Not sure, n (%) 8 (1.4) 1 (0.4) 
Referral, n (%)   
N 545 243 
Self-presenting 82 (15.1) 117 (48.2) 
General practitioner 233 (42.8) 89 (36.6) 
Specialist 199 (36.5) 25 (10.3) 
Surgeon 31 (5.7) 12 (4.9) 
CD, Crohn’s Disease; GI, gastrointestinal; IBD, inflammatory bowel disease. 
aHCP could select all disease locations that applied. 
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Figure legends 
Figure 1. Reported use of oral glucocorticoids (excluding budesonide) during the past year: 
(A) Any oral glucocorticoid use (monotherapy or combined with other therapies), (B) Oral 
glucocorticoid monotherapy use, (C) Any long-term (≥3 months) oral glucocorticoid use 
(monotherapy or combined with other therapies) among any oral glucocorticoid users, (D) 
Long-term (≥3 months) oral glucocorticoid monotherapy use among any oral glucocorticoid 
users. Missing values were not imputed. P-values derived from McNemar test.  
 
Figure 2. Reported use of oral immunosuppressants during the past year. Immunosuppressants 
included azathioprine, 6-mercaptopurine and methotrexate. Missing values were not imputed. 
 
Figure 3. Reported use of anti-TNF biologics during the past year. Biologics included infliximab, 
adalimumab and certolizumab. Missing values were not imputed. 
 
Figure 4. Improved disease course of CD patients during the past year as reported by HCPs. 
Missing values were not imputed. 
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